API

Mechanism of Action

Resmetirom works by specifically targeting the thyroid hormone receptor beta (THR-β) in the liver. Here's a breakdown of the key aspects:

Selective THR-β Activation: Unlike natural thyroid hormones or some drugs, Resmetirom primarily activates THR-β and has minimal effect on THR-α, another thyroid hormone receptor found throughout the body. This targeted action helps minimize potential side effects outside the liver.

Promoting Fatty Acid Metabolism: In a healthy liver, fatty acids are broken down for energy or eliminated. NASH is characterized by an accumulation of fat. Resmetirom activation of THR-β stimulates enzymes involved in fatty acid degradation and oxidation, leading to a reduction in liver fat content.

Potential Anti-inflammatory Effects: While the exact mechanism is still under investigation, THR-β activation by Resmetirom might also play a role in reducing inflammation in the liver, a hallmark of NASH. This could further contribute to improved liver function.

Indication

Resmetirom is approved for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis in adults. NASH is a liver condition characterized by fat accumulation, inflammation, and fibrosis (scarring). Resmetirom helps improve liver function by reducing fat and potentially inflammation.